SCHEMBL1577527

SCHEMBL1577527

CS(=O)(=O)c1ccc(OCc2ccc(C3CCN(C(=O)O)CC3)cn2)cc1

nearest known ligand 0.48

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 15/20 0.48
PRMT5 O14744 1/20 0.40
NPY2R P49146 1/20 0.39
EPHX2 P34913 1/20 0.39
TRPC6 Q9Y210 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1577998 0.90 CA12 (0.47) TRPC6
SCHEMBL1577740 0.89 GPR119 (0.50) GPR119
SCHEMBL1577769 0.89 GPR119 (0.46) GPR119EPHX2
SCHEMBL1577824 0.89 NPY2R (0.42) GPR119PRMT5NPY2RTRPC6
SCHEMBL14141973 0.88 GPR119 (0.50) GPR119PRMT5NPY2R
SCHEMBL1577585 0.88 EPHX2 (0.43) GPR119PRMT5EPHX2
SCHEMBL1577745 0.87 GPR119 (0.49) GPR119
SCHEMBL1577926 0.87 GPR119 (0.65) GPR119
SCHEMBL1577838 0.87 NPC1 (0.44) GPR119PRMT5NPY2RTRPC6
SCHEMBL1577330 0.87 GPR119 (0.51) GPR119PRMT5NPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140018537-A1 GPR119 AGONIST NIPPON CHEMIPHAR CO., LTD. (JP) 2014-01-16 US disclosed
US-8536176-B2 GPR119 agonist NIPPON CHEMIPHAR CO., LTD. (JP) 2013-09-17 US disclosed
US-20110137032-A1 GPR119 AGONIST NIPPON CHEMIPHAR CO., LTD. (JP) 2011-06-09 US disclosed
EP-2311822-A1 GPR119 AGONIST Nippon Chemiphar Co., Ltd. (JP) 2011-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018537-A1 GPR119 AGONIST GPR119, GPR27, GPR52 GPR119 1/4885PRMT5 839/4885NPY2R 55/4885
US-20110137032-A1 GPR119 AGONIST GPR119, GPR27, GPR52 GPR119 1/4885PRMT5 839/4885NPY2R 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.